Diese Seite wurde automatisch übersetzt und die Genauigkeit der Übersetzung wird nicht garantiert. Bitte wende dich an die englische Version für einen Quelltext.

Einarmige, multizentrische Studie zur Bewertung der Akzeptanz und Durchführbarkeit eines digitalen Fernüberwachungstools, konfiguriert für Patienten mit ATTR-CM: ACO-Monitor (ACO-MONITOR)

23. Oktober 2026 aktualisiert von: Bayer

Eine Beobachtungsstudie, um mehr darüber zu erfahren, wie akzeptabel und praktikabel ein digitales Fernüberwachungstool (Luscii) bei Menschen mit Transthyretin-Amyloid-Kardiomyopathie (ATTR-CM) ist

Transthyretin amyloid cardiomyopathy (ATTR-CM) is a heart condition caused by a protein called transthyretin (TTR) building up as amyloid in the heart muscle. This build-up makes the heart stiff and can lead to symptoms of heart failure, such as difficulty breathing, tiredness, swelling in the legs, and reduced ability to be physically active. ATTR-CM occurs in two forms: a hereditary (variant) type caused by changes in genes, and a wild-type form that usually develops with aging.

People living with ATTR-CM are usually cared for at specialist centers, which may require them to travel long distances for appointments. Because of this, visits may be infrequent, and sometimes people only see their doctor once a year. This can make it harder to notice if the disease is getting worse or if there are problems with following their treatment plan. As a result, important changes in health may go unnoticed for several months, which can be risky.

Remote monitoring offers a way for people living with ATTR-CM and their healthcare professionals to stay connected between clinic visits. Recent studies have shown that remote monitoring can help by making it easier to share health information, spot problems earlier, and support people to follow their treatment plans. This can lead to fewer hospital visits and better health outcomes.

Luscii is a digital remote monitoring tool designed to help people living with ATTR-CM and their healthcare professionals stay connected between clinic visits. Luscii has two main parts: Luscii contact, a smartphone app that allows secure messaging and video calls, and Luscii vitals, a clinical software system that organizes health data and can alert the healthcare team if there are changes that need attention. Luscii vitals is a CE-marked medical device used within its approved purpose and does not replace a doctor's judgement.

By making it easier to communicate and share information, Luscii aims to support earlier detection of problems, better management of ATTR-CM, and a more positive experience for people living with this condition.

The main purpose of this observational study, called ACO-MONITOR, is to learn how acceptable and practical Luscii is for people living with ATTR-CM and their healthcare professionals. The study will take place in Austria, Germany, and Italy at three specialist centers. About 60 adults with a diagnosis of hereditary or wild-type ATTR-CM will be invited to take part. There will be no treatments given as part of this study. Instead, participants will use the Luscii app and devices at home to track their health and share information with their healthcare professionals. The study team will provide training on how to use Luscii and will help participants get started.

The study team will look at:

  • How quickly and how often participants and healthcare professionals use Luscii
  • How long Luscii is used by each person
  • How many times participants use Luscii after being reminded
  • How easy Luscii is to use, based on questionnaires for both participants and healthcare professionals

The study will last about 18 months in total, including a 6-month period to invite participants and a 12-month follow-up period. During the study, the study team will:

  • Support participants in using Luscii to share health information from home
  • Monitor how often and how easily Luscii is used
  • Ask participants and healthcare professionals about their experiences using Luscii, including what worked well and what could be improved
  • Record any problems or technical issues with using Luscii By collecting this information, the researchers hope to learn if Luscii can help improve communication, support earlier detection of health problems, and make it easier for people living with ATTR-CM to manage their condition between clinic visits.

Studienübersicht

Status

Noch keine Rekrutierung

Bedingungen

Intervention / Behandlung

Studientyp

Beobachtungs

Einschreibung (Geschätzt)

60

Kontakte und Standorte

Dieser Abschnitt enthält die Kontaktdaten derjenigen, die die Studie durchführen, und Informationen darüber, wo diese Studie durchgeführt wird.

Studienkontakt

Studienorte

      • Heidelberg, Deutschland, 69120
        • Universitätsklinikum Heidelberg
      • Pavia, Italien, 27100
        • Policlinico San Matteo di Pavia
      • Innsbruck, Österreich, 6020
        • Medizinische Universität Innsbruck

Teilnahmekriterien

Forscher suchen nach Personen, die einer bestimmten Beschreibung entsprechen, die als Auswahlkriterien bezeichnet werden. Einige Beispiele für diese Kriterien sind der allgemeine Gesundheitszustand einer Person oder frühere Behandlungen.

Zulassungskriterien

Studienberechtigtes Alter

18 Jahre und älter (Erwachsene, Älterer Erwachsener)

Akzeptiert gesunde Freiwillige

Nein

Studienberechtigte Geschlechter

Alle

Probenahmeverfahren

Wahrscheinlichkeitsstichprobe

Studienpopulation

Eligible participants will be invited by their treating physician and, after providing informed consent, will be observed for approx. 12 months. Patients with an established diagnosis of either wild-type or variant ATTR-CM can be enrolled. Evidence of assessment of all eligibility criteria by the physician or a delegate, as well as enrolment of a participant in the study should be documented in the participant medical records. Medical professionals who are directly involved in the participants' treatment and who have access to and will review the Luscii-captured data for routine care are asked to complete the study-specific questionnaires/forms.

Beschreibung

Inclusion Criteria:

For patients:

  • Adult (≥18 years at the date of signing the informed consent form (ICF)).
  • Diagnosis of either wild-type or variant ATTR-CM.
  • Treatment with a drug approved for ATTR-CM, including newly prescribed therapy at the initial visit.
  • Signed ICF.
  • Access to and basic ability to use a personal smartphone with internet connectivity sufficient to install and operate the Luscii contact application.

For medical professionals:

  • Directly involved in the treatment or clinical management of the enrolled ATTR-CM participants and having access to and reviewing the Luscii-captured data for routine care.
  • Agreement to ICF within the EDC system for the purpose of using Luscii or to complete the HCP Experience Questionnaire.

Exclusion Criteria:

For patients:

  • Participation in an investigational program with interventions outside of routine clinical practice.
  • Patients who are unable to provide consent, including those whose consent would need to be given by a legal representative.

For medical professionals:

  • Any current affiliation with Luscii, Bayer, or any of their affiliates.

Studienplan

Dieser Abschnitt enthält Einzelheiten zum Studienplan, einschließlich des Studiendesigns und der Messung der Studieninhalte.

Wie ist die Studie aufgebaut?

Designdetails

  • Beobachtungsmodelle: COHORT
  • Zeitperspektiven: PROSPECTIVE

Kohorten und Interventionen

Gruppe / Kohorte
Intervention / Behandlung
Wild-type or variant ATTR-CM participants

Participants will be enrolled after the decision to initiate the use of the digital remote monitoring tool, Luscii, as per standard use.

The Luscii tool (CE class IIa certification) will be utilized for remote monitoring of health data specific to ATTR-CM patients. Following the observational nature of the study, no additional interventions will be implemented beyond the standard use of the Luscii tool. Participants will use the Luscii tool continuously throughout the observational period, which is approximately 12 months.

Was misst die Studie?

Primäre Ergebnismessungen

Ergebnis Maßnahme
Maßnahmenbeschreibung
Zeitfenster
Acceptance of Luscii among medical professionals
Zeitfenster: At baseline (initial visit), at 6 months and at 12 months

Defined as their willingness to adopt and engage with the ATTR-CM-specific configuration of Luscii vitals and Luscii contact throughout the study period.

At baseline (initial visit), at 6 months and at 12 months
Acceptance of Luscii among participants with ATTR-CM
Zeitfenster: At baseline (initial visit), at 6 months and at 12 months

Defined as their willingness to adopt and engage with the ATTR-CM-specific configuration of Luscii contact throughout the observational period.

At baseline (initial visit), at 6 months and at 12 months
Feasibility of Luscii for medical professionals
Zeitfenster: At baseline (initial visit), at 6 months and at 12 months

Defined as the practicality of implementing the tool in real-world ATTR-CM care throughout the study period.

At baseline (initial visit), at 6 months and at 12 months
Feasibility of Luscii for participants with ATTR-CM
Zeitfenster: At baseline (initial visit), at 6 months and at 12 months

Defined as the practicality of using the tool in real-world settings throughout the observational period.

At baseline (initial visit), at 6 months and at 12 months
Self-reported acceptance and feasibility of the ATTR-CM-specific Luscii configuration among participants
Zeitfenster: At baseline (initial visit), at 6 months and at 12 months

Measured by the Patient Experience Questionnaire

At baseline (initial visit), at 6 months and at 12 months
Self-reported acceptance and feasibility of the ATTR-CM-specific Luscii configuration among medical professionals
Zeitfenster: At baseline (initial visit), at 6 months and at 12 months

Measured by the Healthcare Professional (HCP) Experience Questionnaire

At baseline (initial visit), at 6 months and at 12 months

Sekundäre Ergebnismessungen

Ergebnis Maßnahme
Maßnahmenbeschreibung
Zeitfenster
Anzahl der Patienten, die beim Screening durchgefallen sind
Zeitfenster: Zu Studienbeginn (Erstbesuch)
Zu Studienbeginn (Erstbesuch)
Grund für das Screening-Versagen
Zeitfenster: Zu Beginn (Erstbesuch)
Zu Beginn (Erstbesuch)
Participant demographic characteristics: age
Zeitfenster: At baseline (initial visit)

Demographic characteristics of participants with ATTR-CM who are willing to use a digital remote tool at baseline (initial visit)

At baseline (initial visit)
Participant demographic characteristics: sex
Zeitfenster: At baseline (initial visit)

Demographic characteristics of participants with ATTR-CM who are willing to use a digital remote tool at baseline

At baseline (initial visit)
Participant demographic characteristics: race
Zeitfenster: At baseline (initial visit)

Demographic characteristics of participants with ATTR-CM who are willing to use a digital remote tool at baseline

At baseline (initial visit)
Clinical characteristics: National Amyloidosis Centre (NAC) Stage
Zeitfenster: At baseline (initial visit)

Categorization of participants according to the NAC Stage into stages I, II, or III, with stage III indicating a higher risk of mortality

At baseline (initial visit)
Clinical characteristics: relevant comorbidities
Zeitfenster: At baseline (initial visit)

ATTR-CM relevant comorbidities

At baseline (initial visit)
Treatment patterns with Acoramidis: ATTR-CM prior medications
Zeitfenster: At baseline (initial visit)

Concomitant medications administered within the past 12 months before initial visit

At baseline (initial visit)
Treatment patterns with Acoramidis: ATTR-CM concomitant medications
Zeitfenster: At baseline (initial visit)

Previously administered ATTR-CM related medications within the past 12 months before initial visit

At baseline (initial visit)

Mitarbeiter und Ermittler

Hier finden Sie Personen und Organisationen, die an dieser Studie beteiligt sind.

Sponsor

Studienaufzeichnungsdaten

Diese Daten verfolgen den Fortschritt der Übermittlung von Studienaufzeichnungen und zusammenfassenden Ergebnissen an ClinicalTrials.gov. Studienaufzeichnungen und gemeldete Ergebnisse werden von der National Library of Medicine (NLM) überprüft, um sicherzustellen, dass sie bestimmten Qualitätskontrollstandards entsprechen, bevor sie auf der öffentlichen Website veröffentlicht werden.

Haupttermine studieren

Studienbeginn (Geschätzt)

30. Oktober 2026

Primärer Abschluss (Geschätzt)

15. April 2028

Studienabschluss (Geschätzt)

15. Mai 2028

Studienanmeldedaten

Zuerst eingereicht

23. April 2026

Zuerst eingereicht, das die QC-Kriterien erfüllt hat

23. April 2026

Zuerst gepostet (Tatsächlich)

29. April 2026

Studienaufzeichnungsaktualisierungen

Letztes Update gepostet (Tatsächlich)

26. Oktober 2026

Letztes eingereichtes Update, das die QC-Kriterien erfüllt

23. Oktober 2026

Zuletzt verifiziert

1. Oktober 2026

Mehr Informationen

Begriffe im Zusammenhang mit dieser Studie

Andere Studien-ID-Nummern

  • 23127

Plan für individuelle Teilnehmerdaten (IPD)

Planen Sie, individuelle Teilnehmerdaten (IPD) zu teilen?

NEIN

Beschreibung des IPD-Plans

Currently, there is no established plan for the sharing of Individual Patient Data (IPD) from this study. The availability of this study's data will later be determined according to Bayer's commitment to the EFPIA/PhRMA 'Principles for responsible clinical trial data sharing.' This pertains to the scope, timepoint, and process of data access. As such, Bayer commits to considering requests from qualified researchers for patient- / study-level clinical trial data, and documents from clinical trials involving medicines and indications approved in the US and EU. However, this commitment does not reflect an active IPD sharing plan. This applies to data on new medicines and indications that have been approved by the EU and US regulatory agencies on or after January 01, 2014. Researchers can use www.vivli.org to request access to IPD and documents from clinical studies to conduct research. Information on Bayer's criteria for listing studies is provided in the member section of the portal.

Arzneimittel- und Geräteinformationen, Studienunterlagen

Studiert ein von der US-amerikanischen FDA reguliertes Arzneimittelprodukt

Nein

Studiert ein von der US-amerikanischen FDA reguliertes Geräteprodukt

Nein

Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .